Equities research analysts expect that Novo Nordisk A/S (NYSE:NVO) will announce earnings of $0.61 per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Novo Nordisk A/S’s earnings. Novo Nordisk A/S posted earnings per share of $0.62 in the same quarter last year, which would suggest a negative year-over-year growth rate of 1.6%. The business is expected to issue its next earnings results on Wednesday, November 7th.

According to Zacks, analysts expect that Novo Nordisk A/S will report full-year earnings of $2.52 per share for the current financial year, with EPS estimates ranging from $2.49 to $2.55. For the next year, analysts anticipate that the company will report earnings of $2.56 per share, with EPS estimates ranging from $2.50 to $2.62. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that that provide coverage for Novo Nordisk A/S.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, August 8th. The company reported $0.68 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.64 by $0.04. The company had revenue of $4.39 billion for the quarter, compared to analysts’ expectations of $4.33 billion. Novo Nordisk A/S had a return on equity of 83.32% and a net margin of 35.95%.

A number of brokerages recently weighed in on NVO. Zacks Investment Research cut Novo Nordisk A/S from a “hold” rating to a “sell” rating in a report on Thursday, June 7th. Sanford C. Bernstein upgraded Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research report on Monday, July 2nd. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $64.00.

Shares of NYSE NVO traded up $0.16 during trading hours on Tuesday, reaching $47.66. 1,084,625 shares of the stock traded hands, compared to its average volume of 1,039,760. The stock has a market cap of $116.46 billion, a price-to-earnings ratio of 18.62, a P/E/G ratio of 2.52 and a beta of 0.65. Novo Nordisk A/S has a 52-week low of $44.28 and a 52-week high of $58.37.

The business also recently declared a special dividend, which was paid on Tuesday, August 28th. Investors of record on Monday, August 20th were given a dividend of $0.4669 per share. The ex-dividend date was Friday, August 17th. This represents a yield of 1.72%. Novo Nordisk A/S’s payout ratio is 27.78%.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of Montreal Can grew its position in Novo Nordisk A/S by 25.7% during the 2nd quarter. Bank of Montreal Can now owns 133,017 shares of the company’s stock worth $6,135,000 after acquiring an additional 27,168 shares during the last quarter. US Bancorp DE grew its position in Novo Nordisk A/S by 16.6% during the 2nd quarter. US Bancorp DE now owns 267,823 shares of the company’s stock worth $12,352,000 after acquiring an additional 38,165 shares during the last quarter. People s United Financial Inc. grew its position in Novo Nordisk A/S by 8.7% during the 2nd quarter. People s United Financial Inc. now owns 23,346 shares of the company’s stock worth $1,076,000 after acquiring an additional 1,866 shares during the last quarter. Greenleaf Trust grew its position in Novo Nordisk A/S by 30.9% during the 2nd quarter. Greenleaf Trust now owns 26,000 shares of the company’s stock worth $1,199,000 after acquiring an additional 6,145 shares during the last quarter. Finally, Gradient Investments LLC grew its position in Novo Nordisk A/S by 18.4% during the 2nd quarter. Gradient Investments LLC now owns 46,313 shares of the company’s stock worth $2,136,000 after acquiring an additional 7,201 shares during the last quarter. Institutional investors and hedge funds own 6.66% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.

Featured Story: Google Finance Portfolio Workaround

Get a free copy of the Zacks research report on Novo Nordisk A/S (NVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.